| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRKG1 |
| Uniprot No | Q13976 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-671aa |
| 氨基酸序列 | SELEEDFAK ILMLKEERIK ELEKRLSEKE EEIQELKRKL HKCQSVLPVP STHIGPRTTR AQGISAEPQT YRSFHDLRQA FRKFTKSERS KDLIKEAILD NDFMKNLELS QIQEIVDCMY PVEYGKDSCI IKEGDVGSLV YVMEDGKVEV TKEGVKLCTM GPGKVFGELA ILYNCTRTAT VKTLVNVKLW AIDRQCFQTI MMRTGLIKHT EYMEFLKSVP TFQSLPEEIL SKLADVLEET HYENGEYIIR QGARGDTFFI ISKGTVNVTR EDSPSEDPVF LRTLGKGDWF GEKALQGEDV RTANVIAAEA VTCLVIDRDS FKHLIGGLDD VSNKAYEDAE AKAKYEAEAA FFANLKLSDF NIIDTLGVGG FGRVELVQLK SEESKTFAMK ILKKRHIVDT RQQEHIRSEK QIMQGAHSDF IVRLYRTFKD SKYLYMLMEA CLGGELWTIL RDRGSFEDST TRFYTACVVE AFAYLHSKGI IYRDLKPENL ILDHRGYAKL VDFGFAKKIG FGKKTWTFCG TPEYVAPEII LNKGHDISAD YWSLGILMYE LLTGSPPFSG PDPMKTYNII LRGIDMIEFP KKIAKNAANL IKKLCRDNPS ERLGNLKNGV KDIQKHKWFE GFNWEGLRKG TLTPPIIPSV ASPTDTSNFD SFPEDNDEPP PDDNSGWDID F |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRKG1重组蛋白的参考文献示例，内容简洁，摘要概括研究核心：
1. **标题**：*Expression and functional characterization of recombinant PRKG1 in mammalian cells*
**作者**：Zhang Y, et al.
**摘要**：该研究在哺乳动物细胞中成功表达并纯化了PRKG1重组蛋白，验证了其cGMP依赖的激酶活性，并应用于细胞信号传导研究。
2. **标题**：*Crystal structure of the regulatory domain of human PRKG1*
**作者**：Huang X, et al.
**摘要**：解析了人PRKG1调控域的高分辨率晶体结构，揭示了cGMP结合后的构象变化，为靶向药物设计提供结构基础。
3. **标题**：*PRKG1 recombinant protein attenuates vascular smooth muscle proliferation via modulating MAPK pathway*
**作者**：Chen L, et al.
**摘要**：研究表明重组PRKG1通过抑制MAPK通路减少血管平滑肌细胞增殖，提示其在治疗血管疾病中的潜力。
4. **标题**：*Development of a high-throughput assay for PRKG1 kinase activity using recombinant protein*
**作者**：Davis R, et al.
**摘要**：开发基于重组PRKG1的高通量激酶活性检测方法，用于筛选调节剂以加速药物发现。
(注：上述文献为示例性质，实际引用时需核实真实性和具体信息。)
PRKG1 (Protein Kinase cGMP-Dependent 1), also known as cGMP-dependent protein kinase type I (PKG I), is a serine/threonine kinase that plays a central role in nitric oxide (NO)/cGMP-mediated signaling pathways. It exists in two isoforms, α and β, generated by alternative splicing. PRKG1 is broadly expressed in tissues such as vascular smooth muscle, platelets, and the nervous system, where it regulates critical physiological processes, including vasodilation, platelet aggregation, and neuronal plasticity. Activation occurs through binding of cGMP, leading to conformational changes that release autoinhibition and enable substrate phosphorylation.
Recombinant PRKG1 proteins are engineered to study its enzymatic activity, structural dynamics, and interactions with downstream targets. These proteins are typically produced in heterologous expression systems (e.g., E. coli, insect cells) and purified for biochemical assays or structural studies. Recombinant PRKG1 retains cGMP-dependent kinase activity and serves as a tool to investigate molecular mechanisms underlying cardiovascular diseases, such as hypertension and atherosclerosis, where dysregulated cGMP signaling is implicated. Mutant variants are also generated to explore phosphorylation-dependent pathways or disease-associated mutations.
Additionally, PRKG1 recombinant proteins aid in drug discovery, particularly for therapies targeting the NO-cGMP-PKG axis, including phosphodiesterase inhibitors (e.g., sildenafil) and soluble guanylate cyclase stimulators. Their use extends to deciphering cross-talk with other signaling cascades (e.g., cAMP/PKA) and validating PKG-specific substrates. Overall, PRKG1 recombinant proteins are indispensable for advancing research into cell signaling, vascular biology, and therapeutic development.
×
